NCT04009824View on ClinicalTrials.gov

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

March 3, 2020

Study Completion Date

February 23, 2021

Conditions
Mosquito-Borne Infectious Diseases
Interventions
BIOLOGICAL

AGS-v PLUS Vaccine

Administered by subcutaneous injection

BIOLOGICAL

Montanide ISA-51 Adjuvant

Administered by subcutaneous injection

BIOLOGICAL

Alhydrogel® Adjuvant

Administered by subcutaneous injection

BIOLOGICAL

Saline Placebo

Administered by subcutaneous injection

Trial Locations (1)

21201-1509

University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore

All Listed Sponsors
collaborator

PepTcell Limited

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04009824 - Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine | Biotech Hunter | Biotech Hunter